Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumers Challenge DMAA Safety After DOD Bans Products

This article was originally published in The Tan Sheet

Executive Summary

Complaints against GNC Holdings Inc., manufacturer Cellucor Sports Nutrition and Woodbolt Distribution and against USPLabs rely on DOD’s decision to ban sales of the product at military exchanges and moves by Canadian regulators to support their arguments.

You may also be interested in...



DMAA Targeted In N.Y. Ban Effort, USP Labs Settles

A New York lawmaker moves to ban DMAA sales in the state, and USP Labs sets aside $2 million to settle class action suit over the product. FDA continues to work with firms that received related warning letters.

DMAA Targeted In N.Y. Ban Effort, USP Labs Settles

A New York lawmaker moves to ban DMAA sales in the state, and USP Labs sets aside $2 million to settle class action suit over the product. FDA continues to work with firms that received related warning letters.

Senate Appropriators Call For Botanical Identity Testing Guidance

A Senate FDA appropriation report says the guidance would enhance the agency’s ability to inspect and assess industry practices for manufacturing botanical dietary supplements. A National Center for Natural Products Research official says most botanical ingredients lack standard identity tests.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS105618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel